Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01036646 · ClinicalTrials.gov registry record

User Performance Evaluation of the INRatio® Prothrombin Time (PT) Monitoring System With a New INRatio Test Strip Designed for Low Sample Volume and Heparin Insensitivity

A clinical trial, sponsored by Abbott RDx Cardiometabolic.

Completed
Registry status
183
Enrollment target

NCT01036646: Completed study, sponsored by Abbott RDx Cardiometabolic.

NCT01036646 is a clinical trial that has completed, run by Abbott RDx Cardiometabolic. The registered enrollment target is 183 participants. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01036646 has completed, sponsored by Abbott RDx Cardiometabolic.

COMPLETED
Registry status
183 participants
Enrollment target

Study Summary

This multi-center study is designed to evaluate the ability of intended lay users (patients on oral anticoagulation therapy, OAT, or their caregivers) to 1) operate the INRatio Prothrombin Time (PT) Monitoring System utilizing the INRatio test strip newly designed for low sample volume and heparin insensitivity, and 2) obtain accurate results for the quantitative determination of International Normalized Ratio (INR) when self-testing using fingerstick capillary blood. Patients will be trained by their healthcare provider using the instructions for use and product labeling provided. The accuracy of the patient INR results will be assessed by comparison to the INR results obtained by the site's trained healthcare professional using the same INRatio system (from a separate fingerstick collected from the same patient at the point-of-care), and with the INR results obtained on venous plasma obtained from the same patient and analyzed at a central laboratory with the Sysmex CA-560 System INR reference method.

Trial Details

FieldValue
Enrollment Target 183 participants
Start Date 2009-08
Est. Completion 2010-09
Abbott RDx Cardiometabolic

14 total trials

What the finished NCT01036646 record still lists

NCT01036646 is an observational study that tracks outcomes without assigning an intervention. The registered 183 participants enrollment target is mid-sized for trials with a published cap.

The record links to 0 conditions, and to 0 interventions.

NCT01036646 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT01036646 about?

NCT01036646 is a clinical study titled "User Performance Evaluation of the INRatio® Prothrombin Time (PT) Monitoring System With a New INRatio Test Strip Designed for Low Sample Volume and Heparin Insensitivity". This multi-center study is designed to evaluate the ability of intended lay users (patients on oral anticoagulation therapy, OAT, or their caregivers) to 1) operate the INRatio Prothrombin Time (PT) Monitoring System utilizing the INRatio test strip newly designed for low sample volume and heparin i...

What is the current status of trial NCT01036646?

This trial is currently completed. The enrollment target is 183 participants. The study started on 2009-08. Estimated completion is 2010-09.

Who is sponsoring clinical trial NCT01036646?

This trial is sponsored by Abbott RDx Cardiometabolic, which has 14 total clinical trials registered on ClinicalTrials.gov.

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT03859297 · 183 participants · NA

    Mechanisms of Rumination Change in Adolescent Depression

  • NCT04270591 · 183 participants · Phase 1

    Assessment of Anti-tumor and Safety in Glumetinib in Patients With c-MET-positive Non-Small Cell Lung Cancer

  • NCT06764615 · 183 participants · Phase 2

    A Continuation Study of TAK-279 in Adults With Ulcerative Colitis (UC) and Crohn's Disease (CD)

  • NCT06872684 · 183 participants · NA

    Safety and Efficacy of Endovascular Treatment of Intracranial Aneurysms With Surpass Elite With GUARDian Flow Diverter (GUARD)

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT01036646, the US trial registry maintained by the National Library of Medicine. NCT01036646 (mid enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.